Shots:
Biohaven & Merus have entered into a research collaboration & license agreement to co-develop bispecific ADCs using the former’s ADC conjugation & payload platform plus Merus’ Biclonics tech platform
As per the terms, Biohaven will develop preclinical ADCs for 3 Merus’ BsAbs (2 developed via Biclonics & 1 in preclinical) & each is…
